Impact of Infectious Disease Spread on Business and Performance
First written in FY2020. 4 of 11 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 2 of 10 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Business and production activities could be suspended due to natural disasters such as earthquakes, typhoons and floods, or infectious diseases.」
The company continues to address the risk of business and production activity stoppages, including due to infectious diseases, through initial response training, company-wide business continuity planning, increased inventories and simulations for switching to outsourced production. - FY2023-Q2RestatedAnnual report
「During the cumulative second-quarter period, in making accounting estimates such as impairment of fixed assets and the recoverability of deferred tax assets, there was no material change in the assumptions related to the spread of infectious disease described in the securities report for the previous consolidated fiscal year.」
The company reconfirmed that there had been no material change from the previous consolidated fiscal year in its accounting assumptions related to the spread of infectious disease. - FY2023-Q1RestatedAnnual report
「During the cumulative first-quarter period, in making accounting estimates such as impairment of fixed assets and the recoverability of deferred tax assets, there was no material change in the assumptions related to the spread of infectious disease described in the securities report for the previous consolidated fiscal year.」
The company reconfirmed that there had been no material change from the previous consolidated fiscal year in its accounting assumptions related to the spread of infectious disease. - FY2022MitigatedAnnual report
「In making accounting estimates such as impairment of fixed assets and the recoverability of deferred tax assets for the current consolidated fiscal year, we believe that the impact of the spread of COVID-19 is minor.」
The company’s assessment of the impact of the infectious disease outbreak has changed from the substantial decline in net sales and losses recorded in the previous fiscal year to considering the accounting impact in the current fiscal year minor. However, the possibility of losses if the outbreak persists remains. - FY2022-Q3RestatedAnnual report
「During the cumulative third-quarter period, in making accounting estimates such as impairment of fixed assets and the recoverability of deferred tax assets, there was no material change in the assumptions related to the spread of infectious disease described in the securities report for the previous consolidated fiscal year.」
The company reconfirmed that there had been no material change from the previous consolidated fiscal year in its accounting assumptions related to the spread of infectious disease. - FY2022-Q2MitigatedAnnual report
「Customer production volumes increased compared with the previous year, which was affected by COVID-19, and net sales increased by ¥24,431 million, or 22.4%, year on year to ¥133,275 million.」
Following the impact of the infectious disease outbreak in the same period of the previous year, net sales increased in Japan, North America and Asia during the cumulative second-quarter period as customer production volumes increased, reducing the year-on-year impact of infectious disease on results. The company also disclosed that there had been no material change in the accounting assumptions related to the spread of infectious disease. - FY2022-Q1MitigatedAnnual report
「Customer production volumes increased compared with the previous year, which was affected by COVID-19, and net sales increased by ¥27,963 million, or 66.4%, year on year to ¥70,072 million.」
Compared with the previous year, when production stoppages and declines at major customers occurred due to the spread of infectious disease, customer production volumes increased in Japan, North America and Asia during the current quarter, reducing the year-on-year impact of infectious disease on results. - FY2021-Q3MaterialisedAnnual report
「(North America) As production at major customers was suspended for a certain period due to the spread of infectious disease, customer production volumes fell sharply. As a result, net sales decreased by ¥13,309 million, or 17.4%, year on year to ¥63,217 million. The operating loss was ¥368 million, mainly due to the decline in net sales. (Asia) As production at some major customers was suspended for a certain period due to the spread of infectious disease, customer production volumes fell sharply. As a result, net sales decreased by ¥14,145 million, or 13.6%, year on year to ¥89,545 million. Operating income declined by ¥1,929 million, or 17.3%, year on year to ¥9,245 million, mainly due to the decline in net sales.」
Production stoppages at major customers due to the spread of infectious disease continued in North America and Asia, materialising in the cumulative third-quarter period as declines in customer production volumes and net sales in both regions, as well as deteriorating earnings. - FY2021-Q2MaterialisedAnnual report
「(North America) As production at major customers was suspended for a certain period due to the spread of infectious disease, customer production volumes fell sharply. As a result, net sales decreased by ¥14,071 million, or 27.1%, year on year to ¥37,822 million. (Asia) As production at some major customers was suspended for a certain period due to the spread of infectious disease, customer production volumes fell sharply. As a result, net sales decreased by ¥20,381 million, or 30.0%, year on year to ¥47,603 million.」
Production stoppages at major customers due to the spread of infectious disease continued in North America and Asia, materialising as declines in net sales in both regions and a consolidated operating loss. - FY2021-Q1WorsenedAnnual report
「As production at major customers was suspended for a certain period due to the spread of infectious disease, customer production volumes fell sharply. As a result, net sales decreased by ¥17,173 million, or 63.5%, year on year to ¥9,870 million. The operating loss was ¥1,792 million, mainly due to the decline in net sales.」
In North America, the impact of the infectious disease outbreak materialised as production stoppages at major customers, resulting in a substantial decline in net sales and an operating loss. In addition to the impact disclosed for the previous full fiscal year, the impact of the risk became more severe as a deterioration in first-quarter results. - FY2020MaterialisedAnnual report
「Business and production activities could be suspended due to natural disasters such as earthquakes, typhoons and floods, or infectious diseases. … The impact of the infectious disease outbreak on our results was a ¥8.6 billion decrease in net sales and a ¥3.0 billion decrease in operating income.」
The company independently disclosed for the first time the risk of business and production activity stoppages due to infectious diseases, and reported that the current fiscal year had actually been affected by a ¥8.6 billion decrease in net sales and a ¥3.0 billion decrease in operating income.